Sex Differences Persist After Durable HIV Control in the Bronx
Women with HIV who achieved sustained virologic suppression in the Bronx still lived longer than men, and the gap was large enough to resemble the survival advantage seen in the general population. In a cohort of 9,999 people receiving care in Montefiore Health System, men had a 32% higher mortality risk than women despite long-term viral control. The finding matters because it shifts attention away from uncontrolled viremia and toward the broader social, biologic, and clinical forces that continue to shape survival after HIV has been brought under control.
This was not a small clinic sample with sparse follow-up. Participants were tracked for a median of 10.7 years, and 2,675 deaths occurred during observation. Entry into the analysis required at least one year of sustained virologic suppression between 1997 and 2021, so the cohort represents people who had already crossed a major treatment threshold. Once that threshold was met, sex-based differences in longevity did not disappear.
Mortality Gap Remained Despite Viral Suppression
The mortality signal was straightforward and clinically consequential. Men experienced a mortality rate ratio of 1.32 compared with women, with a 95% confidence interval of 1.21 to 1.43. In other words, sustained suppression did not flatten the survival difference between women and men. For clinicians caring for aging patients with HIV, this is a reminder that viral suppression is necessary but not sufficient to equalize long-term outcomes.
A one-sentence clinical reality emerges from the data: suppressed HIV still carried a measurable sex gap in survival.
Age-adjusted life-table estimates sharpened the picture. Among people with public insurance and CD4+ T-cell counts of at least 500 cells/μL, remaining life-years at age 30 were 45 for Hispanic women with heterosexual acquisition and 41 for Hispanic men with heterosexual acquisition. Black women and men with heterosexual acquisition had 42 and 38 remaining life-years, respectively. Among people with men who have sex with men acquisition, Hispanic and Black men each had 41 and 44 remaining life-years, depending on race and ethnicity group. These estimates show how survival differences persist even among patients with high CD4 counts and access to public insurance, two markers that usually suggest a relatively stable treatment course.
Race, Ethnicity, and Acquisition Category Shaped Survival
Race and ethnicity were not background descriptors here; they were tied directly to mortality. Compared with Black non-Hispanic participants, Hispanic participants had 19% lower mortality risk, with a rate ratio of 0.81 and a 95% confidence interval of 0.74 to 0.88. Participants categorized as White or other/unknown race and ethnicity had higher mortality risk than Black non-Hispanic participants. Those patterns suggest that survival after virologic suppression is influenced by more than the virus itself. Local care access, neighborhood conditions, comorbidity burden, chronic stress exposure, and the cumulative effects of structural disadvantage likely continue to act long after viral replication is controlled.
The analysis also stratified by HIV acquisition category. Remaining life-years were reported separately for heterosexual acquisition and men who have sex with men acquisition, which is important because transmission category can reflect different social histories, age distributions, and care trajectories. A biologically suppressed patient can still carry a very different mortality risk depending on the interaction of sex, race and ethnicity, and the route through which HIV was acquired. The study’s local design makes those intersections easier to see than they often are in national datasets, where heterogeneity can blur the size and direction of these effects.
What a 4-Year Gap Means at the Bedside
The roughly four-year difference in remaining life-years between women and men is not a statistical footnote. It has practical consequences for counseling, preventive care, and the planning of long-term HIV services. Patients with suppressed HIV are living long enough to accumulate the same chronic-disease hazards seen in other aging populations: cardiovascular disease, malignancy, renal disease, and competing non-AIDS mortality. If men remain at higher risk even after durable suppression, then routine HIV care has to do more than measure viral load and CD4 count.
One sentence captures the bedside implication: the clinical work does not end when the viral load becomes undetectable.
The life-table method used here adds another layer of interpretation. By estimating life expectancy at age 30, the investigators translated mortality rates into remaining years of life, a metric that clinicians and patients can understand more intuitively than rate ratios alone. Those estimates are especially relevant in HIV medicine, where long-term prognosis depends on years of follow-up rather than a single snapshot in time. The approach also helps clarify whether a survival gap is merely theoretical or large enough to matter in daily practice.
Why Local Cohorts Still Matter
This Bronx cohort is valuable because it is geographically concentrated and demographically similar in a way that national studies often are not. Local population analyses can reduce some of the noise that comes from mixing very different care environments, insurance patterns, and racial and ethnic compositions. In a place like the Bronx, where HIV care has long intersected with concentrated poverty and high chronic disease burden, a disaggregated analysis can expose patterns that broader datasets average away.
The biological explanation for the sex difference is not spelled out by the cohort alone, and the study does not need to pretend otherwise. Long-term survival among people with suppressed HIV is likely governed by an interaction of sex-based differences in immune activation, cardiometabolic risk, health-care use, treatment history, and social exposure to stress and disadvantage. The observed gap could also reflect differences in late diagnosis, comorbidity accumulation, or downstream causes of death that are not captured in virologic suppression status.
What remains concrete is the message for HIV care systems: suppression should be treated as a milestone, not an endpoint. Men with controlled HIV in this Bronx cohort still died earlier than women, and mortality varied further by race and ethnicity. The study supports a more granular approach to long-term HIV care, one that tracks survival patterns alongside standard virologic targets and uses local data to identify which groups still carry the heaviest burden.
The analysis was funded by NIH, and the cohort spanned a long period of HIV treatment evolution from 1997 through 2021. That long horizon strengthens the clinical relevance of the findings, but it also means the estimates reflect changing eras of antiretroviral therapy, aging, and background mortality. Future work will need to separate the contributions of treatment era, comorbidity burden, and cause-specific death to explain why the sex gap persists after suppression has been achieved.